Can Candida Cause Cancer? Exploring the Scientific Evidence

Candida has not been classified as a carcinogen, and no health authority lists it alongside tobacco, alcohol, or HPV as an established cause of cancer. But the question is more interesting than a flat “no” would suggest. A growing body of laboratory research, animal studies, and clinical observations points to several routes by which Candida species, especially Candida albicans, can promote tumor development and accelerate existing cancers. The honest answer sits in uncomfortable territory: Candida probably does not initiate cancer the way a virus like HPV does, but it appears capable of nudging tissues closer to malignancy, particularly when chronic infection meets other risk factors.

How Candida Produces a Known Carcinogen

The most concrete mechanistic link between Candida and cancer involves acetaldehyde, a compound the International Agency for Research on Cancer classifies as a Group 1 carcinogen. When Candida encounters even small amounts of alcohol, it metabolizes the ethanol into acetaldehyde. Laboratory studies have shown that C. albicans isolates produce acetaldehyde at concentrations above 100 micromoles per liter, a threshold considered mutagenic, meaning high enough to damage DNA.¹ Multiple Candida species have demonstrated this ability across various alcohol concentrations.²

This matters most in the mouth and upper digestive tract, where Candida colonies sit in direct contact with tissues that are also bathed in alcohol after you drink. The fungus essentially acts as a local acetaldehyde factory. Even moderate drinking in someone who carries heavy oral Candida colonization could result in mucosal cells being exposed to far more acetaldehyde than the alcohol alone would produce. The mechanism helps explain why heavy drinkers with poor oral health and chronic Candida infections face higher risks for cancers of the mouth and esophagus, though separating the fungal contribution from the direct effects of alcohol itself remains difficult.

Chronic Inflammation and the Pro-Tumor Environment

Cancer researchers have long recognized that chronic inflammation can create conditions favorable for tumor growth. Persistent Candida infections generate exactly this kind of environment. When C. albicans colonizes tissue long-term, the immune system’s sustained response produces oxidative stress, shifts cytokine balance toward inflammation, and introduces genomic instability in the surrounding cells.³ Those three factors, oxidative damage, inflammatory signaling, and unstable DNA, are a well-recognized recipe for pushing normal cells toward malignancy.

The inflammation picture gets more specific when you look at the signaling pathways involved. In laboratory experiments, C. albicans infection activates NF-κB, a master switch for inflammatory gene expression, along with pathways involving EGFR and ERK that promote cell survival and migration. Researchers have documented that infection stabilizes a protein called HIF-1α, which drives tumor metabolic reprogramming and new blood vessel formation, both of which tumors need to grow.⁴ In melanoma cells, exposure to C. albicans triggered a measurable shift toward aerobic glycolysis, a hallmark of cancer cell metabolism, driven by p38-MAPK activation.⁵

Candidalysin and Its Role in Tissue Damage

One reason C. albicans specifically keeps surfacing in cancer research, rather than other Candida species, relates to a toxin it produces called candidalysin. When C. albicans shifts from its harmless yeast form to its invasive hyphal form, the hyphae punch into epithelial cells and release candidalysin directly into the tissue. This peptide toxin punches pores in cell membranes, causing direct physical damage.⁶

But candidalysin does more than just injure cells. It hijacks the EGFR signaling pathway, the same receptor that many cancers exploit to fuel their growth. Candidalysin activates both the p38-MAPK arm (which drives inflammation) and the EGFR-ERK arm (which promotes cell survival and proliferation), triggering the transcription factor c-Fos and releasing chemokines that recruit immune cells.⁷ EGFR is so central to cancer biology that several chemotherapy drugs specifically target it. The fact that a fungal toxin repeatedly activates it has raised real concern among researchers studying fungal-cancer interactions.

Where the Clinical Evidence Is Strongest

Oral Cancer

Oral leukoplakia, the white patches that sometimes develop inside the mouth, is a precancerous condition that occasionally transforms into squamous cell carcinoma. A systematic review of observational studies found that Candida infection in leukoplakia was common, ranging from about 7% to 100% of cases depending on the study population, and the review supported the idea that candidal infection promotes cellular changes and dysplasia in these lesions.⁸ Where malignant transformation rates were reported, they varied widely, from about 2.5% to nearly 29%, which speaks to how much other factors like smoking and alcohol influence the outcome.

Animal experiments have added stronger evidence. In a mouse model designed to study oral squamous cell carcinoma, oral candidiasis enhanced cancer progression by amplifying inflammation and triggering overexpression of genes associated with metastasis. The infected mice also showed changes in markers of a process called epithelial-mesenchymal transition, where cells lose their normal anchoring and gain the ability to migrate, a step toward cancer spreading.⁹

Esophageal Cancer

The esophagus is another site where long-standing Candida infection intersects with cancer risk. Case reports and small clinical series have documented esophageal squamous cell carcinoma developing in patients with chronic esophageal candidiasis, particularly in people with an immune condition called chronic mucocutaneous candidiasis.¹⁰ Patients with certain genetic mutations affecting a protein called STAT1 are especially vulnerable: they develop severe, persistent oral and esophageal candidiasis from childhood and face elevated risk of squamous cell carcinoma at those sites.¹¹

A striking finding came from a study of patients with achalasia, a swallowing disorder where food stagnates in the esophagus. Among these patients, those who had a prior esophageal Candida infection showed roughly a 13-fold increased risk of developing esophageal squamous cell carcinoma compared to achalasia patients without such infection, after adjusting for age and sex.¹² That is a large effect size, though it reflects a specific patient population already at elevated risk, not the general public.

Colorectal Cancer

The gut is home to vast fungal communities alongside the better-known bacterial microbiome, and colorectal cancer has become one of the most active areas of research on fungal-cancer links. Studies of Chinese patients with colorectal cancer found significantly higher levels of C. albicans in the gut compared to healthy controls.¹³ A large pan-cancer analysis confirmed that Candida species are highly abundant in gastrointestinal tumor tissues compared to other body sites, with C. albicans the most common representative.¹⁴

That same pan-cancer study made an additional finding worth noting: Candida DNA within gastrointestinal tumors predicted decreased survival. The researchers suggested tumor-associated fungal DNA might eventually serve as a diagnostic or prognostic biomarker, offering a potential clinical application even while the causal question remains unresolved.

The Chicken-or-Egg Problem

The single biggest caveat in all of this research is that finding Candida enriched in or around tumors does not prove the fungus helped create those tumors. Tumors alter their local environment in ways that might simply favor fungal growth: the tissue is often damaged, the immune surveillance is weakened, and the chemical environment shifts. Critical reviews of the evidence have explicitly noted that whether C. albicans infection is a complication of cancer or a contributor to cancer development remains unresolved.¹⁵

This does not invalidate the mechanistic evidence. The acetaldehyde production, the inflammatory signaling, the candidalysin-driven EGFR activation, the metabolic reprogramming, and the EMT-like changes in cancer cells are all real laboratory findings. The issue is that most of the human clinical evidence is observational: it shows associations, not proof of direction. The esophageal achalasia study, for instance, is suggestive because the Candida infection preceded the cancer, but it still cannot rule out that whatever caused the infection vulnerability also independently raised cancer risk.

When Candida Teams Up with Bacteria

One of the more recent and compelling findings is that Candida does not necessarily act alone. In colorectal cancer, researchers discovered that C. albicans synergizes with Fusobacterium nucleatum, a bacterium already strongly linked to colorectal cancer, to accelerate cancer progression. In animal models, mice inoculated with both the fungus and the bacterium developed more advanced tumors than mice exposed to either microbe on its own, and this combination was associated with worse patient outcomes.¹⁶ The interaction was mediated by specific surface proteins on the two organisms that let them physically bind together.

This polymicrobial angle complicates the picture further. In the real gut, Candida never exists in isolation. It shares space with hundreds of bacterial and fungal species, and the interactions among them may matter as much as any single organism’s effects. It also means that studying Candida’s cancer-promoting potential in isolation might underestimate its real-world impact.

Beyond the Digestive Tract

Most research has focused on oral, esophageal, and colorectal cancers, but evidence is emerging from other sites too. A systematic review and meta-analysis of fungal infection in cervical cancer found that fungal infection prevalence was about 19% in cervical cancer patients compared with 8% in those without cancer. Fungal infection was more common in invasive cervical cancer than in precancerous lesions or normal tissue, suggesting a link to later-stage disease rather than to cancer initiation.¹⁷

Reviews have also examined Candida’s role in breast cancer, identifying mechanisms like virulence factor production, stimulation of pro-inflammatory mediators, and immune cell activation as potential pathways through which the fungus could promote malignancy.¹⁸ In melanoma, gut C. albicans levels showed a significant relationship with disease progression: patients with high gut C. albicans abundance were roughly twice as likely to experience melanoma progression compared to those with low levels.¹⁹

How Candida Makes Cancer Cells Move

Several studies have examined what happens to cancer cells at a cellular level when they encounter C. albicans. In colorectal cancer cell lines, infection triggered changes resembling epithelial-mesenchymal transition: the cells downregulated E-cadherin (a molecule that normally keeps cells anchored in place), altered the sugar coatings on their surface proteins, and became more motile. When researchers blocked the enzyme responsible for those sugar modifications, the increased motility stopped.²⁰ These findings are from cell culture and preprint studies, so they carry less weight than clinical data, but they provide a mechanistic explanation for how Candida presence in a tumor might make that tumor more aggressive even if the fungus did not cause it in the first place.

Immune Vulnerability and Genetic Susceptibility

Not everyone’s immune system handles Candida equally, and some of the strongest clinical links between Candida and cancer appear in people with specific immune deficiencies. The CARD9 protein, part of the innate immune system’s antifungal defense, is one example. Both mice and humans who lack functional CARD9 are more susceptible to fungal and bacterial infections.²¹ CARD9 has also been linked to tumor immunity, suggesting that the same genetic vulnerability that lets Candida thrive might simultaneously weaken the body’s ability to detect and destroy early cancer cells.

The STAT1 gain-of-function mutations mentioned earlier in relation to esophageal cancer represent another genetic intersection. These patients cannot effectively clear Candida, leading to chronic mucosal infection from early life. Whether the cancer in these patients is driven primarily by the chronic fungal infection, the disrupted immune surveillance, or both remains an open question, but the fact that these two vulnerabilities travel together is hard to dismiss as coincidence.

Antifungal Drugs as Potential Cancer Treatments

If Candida genuinely promotes cancer, an obvious follow-up question is whether treating the fungal infection could slow the cancer. Early evidence is provocative. In animal models of invasive pancreatic cancer, the antifungal drug amphotericin B effectively inhibited cancer progression. In a population-based study from Sweden, colorectal cancer patients who received the antifungal terbinafine after diagnosis had a lower risk of death and metastasis, and follow-up mechanistic work showed that terbinafine could inhibit fungus-driven immune suppression and restore antitumor immune responses.²²

Some antifungals appear to have direct anticancer properties independent of their antifungal activity. Itraconazole and terbinafine target signaling pathways that tumors rely on for growth, including pathways controlling cell survival, blood vessel formation, and resistance to chemotherapy. In preclinical studies, these drugs induced cancer cell death, blocked angiogenesis, and made oral squamous cell carcinoma cells more sensitive to standard chemotherapy and radiation.²³ These are still mostly preclinical findings, and no one should start taking antifungals to prevent cancer. But the dual activity of these drugs, hitting both the fungus and the tumor, has researchers paying attention.

Candida and Immunotherapy Responses

Cancer immunotherapy, particularly drugs that block PD-1 to unleash the immune system against tumors, has transformed treatment for several cancers. The gut mycobiome appears to influence how well these treatments work. Specific fungal taxa, including Candida and Malassezia, have been associated with changes in the tumor microenvironment and modulation of host immunity that affect therapy outcomes.²⁴

The relationship is not straightforward. In melanoma patients, high gut C. albicans was linked to worse responses to anti-PD-1 therapy.¹⁹ Yet in esophageal cancer, a different Candida species, Candida boidinii, actually enhanced anti-PD-1 efficacy in a mouse model, with corresponding immune changes that validated predictions from human clinical data.²⁵ The species-specific direction of these effects underscores how simplistic it would be to label all Candida as uniformly cancer-promoting. Different species, different tissues, and different treatment contexts can flip the relationship entirely.

Fungi Inside Tumors Are More Common Than Anyone Expected

Until recently, the assumption was that solid tumors were essentially sterile environments. That changed in 2022 when two landmark studies independently demonstrated that fungi are present inside human tumors across many cancer types. These fungal communities are low in abundance but surprisingly ubiquitous, and they show cancer-type-specific patterns, meaning the fungal profile inside a pancreatic tumor looks different from the one inside a breast tumor or a lung tumor.¹⁴ The discovery launched an entirely new subfield examining the “tumor mycobiome” and its potential role in cancer biology.

Whether these intratumoral fungi are passengers, hitchhikers exploiting a damaged neighborhood, or active participants shaping the tumor remains the central question. Some researchers have described the relationship as a paradigm shift in thinking about cancer pathogenesis, noting that specific mycobiome types can predict survival outcomes even if the causal direction is not yet established. This is where the field sits today: the associations are strong enough and the mechanistic evidence plausible enough that few serious researchers dismiss the connection, but the gap between “biologically plausible contributor” and “established cause” has not been closed for any human cancer.